Skip to content
DataLookout
Menu

CARE-NETNCT07939113

Real-World Effectiveness of Cabozantinib in Advanced Neuroendocrine Tumors: A Retrospective Multicenter Study Using the GTE-RENATEN National Database

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

To evaluate, in real-world clinical practice, the Disease Control Rate (DCR) achieved with cabozantinib among patients with advanced or metastatic well-differentiated NETs treated between January 2020 and August 2026.
Timeframe: Retrospective data between January 2020 and August 2026

Arms and interventions

Advanced Neuroendocrine Tumors treated by cabozantinib follow in ENDOCAN RENATEN network

Adults ≥18 years. Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids Metastatic or unresectable disease. Cabozantinib initiated between January 2020 and August 2026

Sites

1 site in 1 country

  • Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot HospitalLyon, France